YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Bristol Myers Squibb BMY is banking on label expansion of existing drugs and approval of new drugs to further propel its growth portfolio. Camzyos (mavacamten) is one of the key drugs in this product portfolio. The drug is currently approv…
Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations an…
Cytokinetics, Incorporated Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIR…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Cantor Fitzgerald initiated Lexicon Pharmaceuticals (LXRX [https://seekingalpha.com/symbol/LXRX]) at overweight, saying that it is optimistic on upcoming phase 3 data of the SGLT1/2 in…
Investing.com -- B. Riley analyst Mayank Mamtani has identified top biotech picks heading into third-quarter 2026 earnings season, following the Federal Reserve's 25 basis point rate hike to 4.00%, its first increase since July 2023. The u…
Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for "Global Equity Strategy". The letter can be downloaded here. Global markets delivered strong gains during the quarter, suppo…
Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 sha…
Cytokinetics, Incorporated Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is October 2, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026…
Friday, September 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Marvell Technology,…
Cytokinetics (CYTK) likely has the upper hand in its patent dispute with Bristol-Myers Squibb (BMY) PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
The diversified S&P 500 (SNPINDEX: ^GSPC) and the technology-heavy Nasdaq-100 are two widely followed stock market indexes that are packed with America's highest-quality companies. They have returned 12.7% and 17% respectively so far in 20…
Cytokinetics, Incorporated (NASDAQ:CYTK) has reported detailed late-stage results that could support an expansion of aficamten into a form of genetic heart disease that currently does not have any approved treatments. Aficamten is already…
Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor con…
Cytokinetics, Incorporated CYTK recently announced additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints in Adults with Non-Obstructive HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients wi…
[A stack of coins is shown on a blue background with a world map] IURII KRASILNIKOV The put-call ratio for the iShares Russell 2000 ETF (IWM [https://seekingalpha.com/symbol/IWM]) surged to 3.58, with Barchart saying the reading marked the…
Cytokinetics (CYTK) is back in focus after presenting new Phase 3 data for aficamten in hypertrophic cardiomyopathy at the European Society of Cardiology Congress 2026, alongside plans for a supplemental FDA filing. Cytokinetics shares hav…
Cytokinetics (NasdaqGS: CYTK) reports positive Phase 3 results for aficamten (MYQORZO) in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. The trial is described as the first successful clinical study in this indicati…
Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock's prior closing price. The move comes after the company priced its initial public offering…
Cytokinetics, Incorporated Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Acros…
Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday. Continue Reading
[Cytokinetics headquarters in Silicon Valley] Sundry Photography/iStock Editorial via Getty Images Cytokinetics (CYTK [https://seekingalpha.com/symbol/CYTK]) traded lower on Friday after releasing full data from a late-stage trial designed…
Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday. Continue Reading
Cytokinetics, Incorporated ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental…
Bristol Myers Squibb BMY is banking on label expansion of existing drugs and approval of new drugs to further propel its growth portfolio. Camzyos (mavacamten) is one of the key drugs of this product portfolio. The drug is currently approv…
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
Robert I. Blum, President & CEO of Cytokinetics (NASDAQ:CYTK), reported the sale of 7,500 shares on Aug. 10, 2026, as disclosed in a recent SEC Form 4 filing. Transaction summary Metric Value Transaction value $575,700 Shares sold (direct)…
Cytokinetics, Incorporated Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event…
Shares of Cytokinetics, Incorporated CYTK have gained 20.5% year to date compared with the industry's growth of 7%. The stock has also outperformed the sector and the S&P 500 Index during this timeframe. The company entered a pivotal phase…
Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 14, 2026 it granted stock options to purchase an aggregate of 27,565 shares…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Cytokinetics stock has delivered strong multi year returns, yet its latest valuation checks point to a more mixed pictu…
Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss…
Launched on July 24, 2000, the iShares Russell 2000 Value ETF (IWN) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Value segment of the US equity market. The fund is sponsored by Blackrock…
This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Cytokinetics Inc (NASDAQ:CYTK) reported strong com…
Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to a loss of $1.12 per share a year ago. These figures are adjusted for non-recurring items. This qu…
Cytokinetics, Incorporated MYQORZO® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 M…
The market expects Axsome Therapeutics (AXSM) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the com…